APRICOXIB Cyclooxygenase-2 (COX-2) Inhibitor Oncolytic

被引：0
|
作者：
Edelman, Martin J. [1 ]
机构：
[1] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA
来源：
DRUGS OF THE FUTURE | 2011年 / 36卷 / 07期
关键词：
CS-706; R-109339; TG-01; TP-1001; TP-2001; METASTATIC BREAST-CANCER; CELL LUNG-CANCER; DOUBLE-BLIND; CARDIOVASCULAR EVENTS; COVALENT BINDING; PHASE-II; CELECOXIB; EXPRESSION; ROFECOXIB; CS-706;
D O I：
10.1358/dof.2011.036.07.1608943
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Overexpression of cyclooxygenase-2 (COX-2) has been implicated as a tumor-initiating and -promoting event for a number of common solid tumors, including lung, breast and colon cancer. Considerable epidemiological evidence supports COX-2 inhibition as a method of chemoprevention. Inhibition of COX-2 in laboratory models has been demonstrated to be antineoplastic both by itself and in combination with cytotoxic and targeted agents. Apricoxib is a novel, potent and selective inhibitor of COX-2 currently under development as an anti-cancer agent, as well as an analgesic. This review discusses the pharmacology, preclinical and clinical results with apricoxib, focusing on its potential use in oncology.
引用
收藏
页码：503 / 509
页数：7
相关论文
共 50 条
  • [31] Cyclooxygenase-2 (COX-2) in carcinogenesis and selective cox-2 inhibitors for chemoprevention in gastrointestinal cancers
    Fujimura T.
    Ohta T.
    Oyama K.
    Miyashita T.
    Miwa K.
    Journal of Gastrointestinal Cancer, 2007, 38 (2-4) : 78 - 82
  • [32] Regulated cyclooxygenase-2 (Cox-2) expression to investigate the role of Cox-2 in gastric cancer
    Griffin, NM
    Cox, CM
    Scully, GM
    Doherty, GA
    Fitzgerald, DJ
    GASTROENTEROLOGY, 2004, 126 (04) : A49 - A49
  • [33] Glycosylation of human cyclooxygenase-2 (COX-2) decreases the efficacy of certain COX-2 inhibitors
    Sevigny, Mary B.
    Graham, Kamara
    Ponce, Esmeralda
    Louie, Maggie C.
    Mitchell, Kylie
    PHARMACOLOGICAL RESEARCH, 2012, 65 (04) : 445 - 450
  • [34] Expression of cyclooxygenase-2 (COX-2) in human esophageal cancer and in vitro inhibition by a specific COX-2 inhibitor, NS-398
    Yu, HP
    Shi, LY
    Lu, WH
    Su, YH
    Li, YY
    Xu, SQ
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2004, 19 (06) : 638 - 642
  • [35] Cyclooxygenase-2 (COX-2) expression in primary acquired melanosis
    Oliver, KM
    Lima, GS
    Caissie, AL
    Marshall, JCA
    Deschenes, J
    Burnier, MN
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2002, 43 : U242 - U242
  • [36] Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases
    Minghetti, L
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2004, 63 (09): : 901 - 910
  • [37] Cyclooxygenase-2 (Cox-2) expression and angiogenesis in intracranial ependymomas
    Onguru, O.
    Kurt, B.
    Gunhan, O.
    Soylemezoglu, F.
    CLINICAL NEUROPATHOLOGY, 2006, 25 (05) : 216 - 220
  • [38] Cyclooxygenase-2 (COX-2): a molecular target in prostate cancer
    Gallego, G. Aparicio
    Prado, S. Diaz
    Fonseca, P. Jimenez
    Campelo, R. Garcia
    Espinosa, J. Cassinello
    Aparicio, L. M. Anton
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2007, 9 (11): : 694 - 702
  • [39] Cyclooxygenase-2 (COX-2) expression in canine intracranial meningiomas
    Rossmeisl, J. H., Jr.
    Robertson, J. L.
    Zimmerman, K. L.
    Higgins, M. A.
    Geiger, D. A.
    VETERINARY AND COMPARATIVE ONCOLOGY, 2009, 7 (03) : 173 - 180
  • [40] Clinical significance of cyclooxygenase-2 (COX-2) in multiple myeloma
    Trojan, A
    Tinguely, M
    Vallet, S
    Seifert, B
    Jenni, B
    Zippelius, A
    Witzens-Harig, M
    Mechtersheimer, G
    Ho, AD
    Goldschmidt, H
    Jäger, D
    Boccadoro, M
    Ladetto, M
    SWISS MEDICAL WEEKLY, 2006, 136 (25-26) : 400 - 403
12345